Angitia Bio lands $130m to advance human trials of musculoskeletal health drugs

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company’s osteoporosis program completes enrollment in Phase 2 trial focused on treating the disease in postmenopausal women.

US biotech Angitia Biopharmaceuticals has secured $130 million in a Series D financing to fuel the development of new medicines for musculoskeletal diseases. The money will be used to advance several clinical-stage programs, with its Phase 2 osteoporosis candidate most notable from a longevity perspective.  

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE